Skip to content

    Recently Viewed

      Listening...

      Home / Our Company / Our societal impact / Global Health Equity /
      Tuberculosis news & updates

      Tuberculosis news & updates

      PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials

      Public-private collaboration to evaluate five antimicrobial agents across two combination regimens for treating both drug-susceptible and drug-resistant forms of TB with shorter treatment durations

      “We want a world without tuberculosis in our lifetimes”

      Healthcare providers who contracted TB on the job. A microbiologist researching new treatments. An activist ensuring attention is paid to one of the world’s greatest health threats. These young leaders share one goal: to help end TB.

      Johnson & Johnson Announces Series of Youth Initiatives Aimed at Helping to Empower a Generation to End Tuberculosis

      Initiatives will focus on engaging young people as advocates in the fight against TB in high-burden countries and regions, including China, India, Southeast Asia and South Africa Youth can help drive health-seeking behavior in themselves and those around them, which is critical to finding the “missing millions” of people living with undiagnosed TB These efforts are part of the Company’s 10-year initiative aimed at helping to bring an end to the global TB epidemic, which claimed 1.5 million lives in 2020

      Johnson & Johnson Announces Series of Youth Initiatives Aimed at Helping to Empower a Generation to End Tuberculosis

      Initiatives will focus on engaging young people as advocates in the fight against TB in high-burden countries and regions, including China, India, Southeast Asia and South Africa Youth can help drive health-seeking behavior in themselves and those around them, which is critical to finding the “missing millions” of people living with undiagnosed TB These efforts are part of the Company’s 10-year initiative aimed at helping to bring an end to the global TB epidemic, which claimed 1.5 million lives in 2020

      Johnson & Johnson is proud to lead efforts to outpace antimicrobial resistance

      The company’s efforts seek to address this rising public health threat and protect the backbone of modern medicine

      Johnson & Johnson Launches Network of Global Health Discovery Centers that Aim to Speed Up Science and Tackle Pandemic Threats

      J&J Centers for Global Health Discovery (J&J Centers) are a new cornerstone of the Company’s efforts to solve the world’s most pressing health challenges The first J&J Satellite Center is hosted at the London School of Hygiene & Tropical Medicine (LSHTM) and focused on addressing the threat of antimicrobial resistance and tuberculosis J&J Centers will include collaborations with renowned academic institutions that accelerate potentially lifesaving innovations from the lab to the last mile

      Johnson & Johnson Announces Five Initiatives to Help Find the ‘Missing Millions’ of Undiagnosed People Living with Tuberculosis

      Three out of 10 people with TB go undiagnosed and untreated, a situation exacerbated by health disruptions caused by the COVID-19 pandemic Collaborating with the Global Fund, USAID, PATH and others will help more people access TB care These initiatives build on Johnson & Johnson’s longstanding commitment to tackling TB and addressing health inequity in high-burden countries

      2 pandemics, 1 goal: Meet 4 innovators with high-tech ideas for fighting tuberculosis in the time of COVID-19

      Despite being preventable and curable, tuberculosis is one of the world’s deadliest infectious diseases—and COVID-19 is making it even harder to diagnose and treat it. Enter these healthcare visionaries, who’ve made it their mission to move the world closer to the goal of ending tuberculosis.

      3 ways Johnson & Johnson is innovating to help fight tuberculosis

      It’s one of the world’s deadliest infectious diseases, killing more people each year than HIV/AIDS and malaria combined. We’re taking a look back at the strides the company has made in fighting this preventable illness to help bring us closer to a tuberculosis-free world.

      Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries

      Joint efforts aim to accelerate scale-up of WHO-recommended all-oral treatment regimens – a transition urgently needed to help protect the health of people with drug resistant-tuberculosis who are particularly vulnerable during COVID-19 pandemic In 2020, the initiative aims to reach at least 125,000 patients and could save National TB Programs in low- and middle-income countries up to USD$16 million

      First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis

      A new global collaboration of philanthropic, non-profit and private sector organizations will work together to accelerate the development of novel TB treatment regimens for all TB patients. The global collaboration aims to create treatment regimens comprised of medicines to which there is limited or no drug resistance and that are ready for phase 3 development. The regimens could be an important step toward addressing the current global challenges around TB treatment complexity, and the diagnosis and treatment of drug-resistant TB.

      From actor to advocate: A new MTV star opens up about the TB epidemic

      When Syed Raza Ahmed took a role playing a 20-something living with TB, he knew he had a responsibility to educate others and help reduce stigma. As his MTV show debuts, he sat down with us to reveal what he’s learned about the world’s deadliest infectious disease.

      Johnson & Johnson Collaborates with The MTV Staying Alive Foundation to Launch Youth-Focused “Edutainment” Campaign Focused on Tuberculosis & Other Health Issues in India

      Program aims to raise awareness and reduce stigma of TB among young people in India, as part of Johnson & Johnson’s 10-year initiative to combat world’s leading infectious disease killer

      Statement on U.S. FDA Approval of Pretomanid as Part of Bedaquiline-Containing “BPaL” Regimen

      Attributable to Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson

      The quest to end tuberculosis: 17 memorable moments in innovation

      Johnson & Johnson has been instrumental in helping bring us closer to a TB-free world through its groundbreaking work with multidrug-resistant TB.

      Breath for life: The Johnson & Johnson program that’s helping eradicate tuberculosis in Vietnam

      In just two years, a unique collaboration has had an unprecedented impact in the fight against the national epidemic. In honor of World TB Day on March 24, we traveled to one of its most affected provinces to report on the project’s remarkable results.

      Johnson & Johnson Joins First Industry-wide Call for New Collective Action to Address Antimicrobial Resistance

      More than 80 International Pharmaceutical, Generics, Diagnostics and Biotechnology Companies Agree to a Joint Declaration to Combat Rising Global Health Challenge

      Johnson & Johnson Announces New Grant to Harvard Medical School to Combat Drug-Resistant Tuberculosis

      New collaboration will help address significant global unmet needs in pediatric drug-resistant tuberculosis (DR-TB) treatment and optimize use of existing DR-TB treatments
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.